Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Aytug Kizilors"'
Autor:
Syed A. Mian, Linda Ariza‐McNaughton, Fernando Anjos‐Afonso, Remisha Gurung, Sophie Jackson, Aytug Kizilors, John Gribben, Dominique Bonnet
Publikováno v:
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)
Abstract Immunodeficient mouse models are widely used for the assessment of human normal and leukemic stem cells. Despite the advancements over the years, reproducibility, as well as the differences in the engraftment of human cells in recipient mice
Externí odkaz:
https://doaj.org/article/ec46a21af9d6473380851a2260b85562
Autor:
Hugues de Lavallade, Aytug Kizilors
Publikováno v:
European Medical Journal Oncology, Vol 4, Iss 1, Pp 86-95 (2016)
Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have become the standard therapy for chronic myeloid leukaemia (CML). While allogeneic hematopoietic stem cell transplant is a recognised curative treatment for CML
Externí odkaz:
https://doaj.org/article/7f14c9d406f54e688bd967a1fd93adb8
Autor:
Syed A. Mian, Alexander E. Smith, Austin G. Kulasekararaj, Aytug Kizilors, Azim M. Mohamedali, Nicholas C. Lea, Konstantinos Mitsopoulos, Kevin Ford, Erick Nasser, Thomas Seidl, Ghulam J. Mufti
Publikováno v:
Haematologica, Vol 98, Iss 7 (2013)
The recent identification of acquired mutations in key components of the spliceosome machinery strongly implicates abnormalities of mRNA splicing in the pathogenesis of myelodysplastic syndromes. However, questions remain as to how these aberrations
Externí odkaz:
https://doaj.org/article/71c6b0a59677481d9e474cf9fa69aecb
Autor:
Aytug Kizilors, Roberto Passera, Maadh Aldouri, Christopher Pocock, Syed A Mian, Robin M. Ireland, Jamal Anwar, Antonio Pagliuca, Emily Bart-Smith, Franck E. Nicolini, Elena Crisà, Patrick Harrington, Steve Best, Austin G. Kulasekararaj, Tim Corbett, Ghulam J. Mufti, Clare Wykes, Simon Weston-Smith, Donal P. McLornan, Sophie E. Jackson, Richard Gale, Nicholas Lea, Kavita Raj, Hugues de Lavallade
Publikováno v:
The Lancet Haematology. 6:e276-e284
Kinase domain mutations in BCR-ABL1 are associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Next-generation sequencing (NGS) allows detection of low-level kinase domain mutations, but its relevance in
Autor:
Katayoon Shirneshan, Vera Adema, Steven Best, Nicholas Lea, Julie Schanz, Guillermo Sanz, Elena Crisà, Francesc Solé, Esperanza Such, Detlef Haase, Ghulam J. Mufti, Aytug Kizilors, Dario Ferrero, Ana Belen Valencia Martinez, Barbara Hildebrandt, José Cervera, Ulrich Germing, Syed A Mian, Valeria Santini, Austin G. Kulasekararaj
Publikováno v:
Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Monosomy 7 [-7] and/or partial loss of chromosome 7 [del(7q)] are associated with poor and intermediate prognosis, respectively, in myelodysplastic syndromes (MDS), but somatic mutations may also play a key complementary role. We analyzed the impact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f550a15f895795c1f0183eeb20c2a76b
http://hdl.handle.net/2158/1193444
http://hdl.handle.net/2158/1193444
Autor:
Sahar Mansour, Judith C. W. Marsh, Petra Muus, Shreyans Gandhi, Nicholas Lea, Simon Slade, Aytug Kizilors, Victoria Potter, Sudarshan Gurung, Alice Mason, Andrea Da Silva, Robin M. Ireland, Ghulam J. Mufti, Austin G. Kulasekararaj, Jie Jiang, Varun Mehra
Publikováno v:
Blood. 134:3749-3749
Introduction Telomere length is shortened in patients with idiopathic aplastic anemia (AA) and other bone marrow failure disorders (BMFD) and predicts risk of clonal evolution (CE), relapse and overall survival (OS). Telomereopathies predominantly ca
Autor:
Hugues de Lavallade, Francois-Xavier Mahon, Fanny Robbesyn, Stephane Morisset, Sophie E. Jackson, Delphine Rea, Françoise Huguet, Claudine Chollet, Stéphanie Dulucq, Franck E. Nicolini, Agnès Guerci-Bresler, Gabriel Etienne, Aytug Kizilors
Publikováno v:
Blood. 134:664-664
Introduction The acquisition of ABL1 Kinase Domain (KD) mutations represent the most frequent resistance mechanism in CP-CML patients (pts) treated with tyrosine kinase inhibitors (TKI). Currently, the standard assay relies on a poorly sensitive tech
Autor:
Kate Rothwell, Michael Thompson, Joanne Ewing, Patrick Harrington, Hugues de Lavallade, Sebastian Francis, Oliver G. Ottmann, Aytug Kizilors, Mhairi Copland, Anshu Garg, Jenny Byrne, Priyanka Mehta, Sophie E. Jackson, Sandra Hassan, Deepti Radia, Edward Belsham, Heather Oakervee, P Cahalin, Srinivas Pillai, Nicholas Lea, Rachel Greig
Publikováno v:
Blood. 134:2935-2935
Introduction Kinase domain mutations in the BCR-ABL1 gene are associated with resistance to tyrosine kinase inhibitors (TKI) in chronic myeloid leukaemia (CML). Next-generation Sequencing (NGS) allows detection of low-level kinase domain mutations as
Autor:
Nicholas Lea, Evangelia Dimitriadou, Sophie E. Jackson, Anita Aresatnam, Robin M. Ireland, Richard Gale, Isabel Sa, Deepti Radia, Timothy Corbett, Vijayavalli Dhanapal, Luke Ficinksi, Antonio Pagliuca, Sandra Hassan, Patrick Harrington, Ghulam J. Mufti, Joel Newman, Hugues de Lavallade, Claire N. Harrison, Elena Crisà, Aytug Kizilors
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S293-S294
Autor:
Robin M. Ireland, Robert J. Flanagan, Aytug Kizilors, Kathryn Lang, Alessandra Bisquera, Ghulam J. Mufti, Aloysius Ho, Sarah L. Belsey, Hugues de Lavallade
Publikováno v:
Therapeutic drug monitoring. 39(5)
The standard dose of imatinib for the treatment of chronic-phase chronic myeloid leukemia (CML) is 400 mg·d. A predose plasma imatinib concentration of1 mg·L is associated with improved clinical response. This study aimed to assess the plasma imati